Literature DB >> 34446452

To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy.

Sandy Srinivas1, Andrei Iagaru2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34446452      PMCID: PMC8612330          DOI: 10.2967/jnumed.121.263035

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  12 in total

1.  Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.

Authors:  Andreas Delker; Wolfgang Peter Fendler; Clemens Kratochwil; Anika Brunegraf; Astrid Gosewisch; Franz Josef Gildehaus; Stefan Tritschler; Christian Georg Stief; Klaus Kopka; Uwe Haberkorn; Peter Bartenstein; Guido Böning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-29       Impact factor: 9.236

2.  The case for obtaining a diagnostic whole-body scan prior to iodine 131 treatment of differentiated thyroid cancer.

Authors:  I Ross McDougall
Journal:  Thyroid       Date:  2009-08       Impact factor: 6.568

3.  EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).

Authors:  Clemens Kratochwil; Wolfgang Peter Fendler; Matthias Eiber; Richard Baum; Murat Fani Bozkurt; Johannes Czernin; Roberto C Delgado Bolton; Samer Ezziddin; Flavio Forrer; Rodney J Hicks; Thomas A Hope; Levant Kabasakal; Mark Konijnenberg; Klaus Kopka; Michael Lassmann; Felix M Mottaghy; Wim Oyen; Kambiz Rahbar; Heiko Schöder; Irene Virgolini; Hans-Jürgen Wester; Lisa Bodei; Stefano Fanti; Uwe Haberkorn; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-22       Impact factor: 9.236

Review 4.  Toward achieving precision health.

Authors:  Sanjiv Sam Gambhir; T Jessie Ge; Ophir Vermesh; Ryan Spitler
Journal:  Sci Transl Med       Date:  2018-02-28       Impact factor: 17.956

5.  PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.

Authors:  Clemens Kratochwil; Frederik L Giesel; Melsa Stefanova; Martina Benešová; Marcus Bronzel; Ali Afshar-Oromieh; Walter Mier; Matthias Eder; Klaus Kopka; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2016-03-16       Impact factor: 10.057

6.  German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.

Authors:  Kambiz Rahbar; Hojjat Ahmadzadehfar; Clemens Kratochwil; Uwe Haberkorn; Michael Schäfers; Markus Essler; Richard P Baum; Harshad R Kulkarni; Matthias Schmidt; Alexander Drzezga; Peter Bartenstein; Andreas Pfestroff; Markus Luster; Ulf Lützen; Marlies Marx; Vikas Prasad; Winfried Brenner; Alexander Heinzel; Felix M Mottaghy; Juri Ruf; Philipp Tobias Meyer; Martin Heuschkel; Maria Eveslage; Martin Bögemann; Wolfgang Peter Fendler; Bernd Joachim Krause
Journal:  J Nucl Med       Date:  2016-10-20       Impact factor: 10.057

7.  [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

Authors:  Michael S Hofman; Louise Emmett; Shahneen Sandhu; Amir Iravani; Anthony M Joshua; Jeffrey C Goh; David A Pattison; Thean Hsiang Tan; Ian D Kirkwood; Siobhan Ng; Roslyn J Francis; Craig Gedye; Natalie K Rutherford; Andrew Weickhardt; Andrew M Scott; Sze-Ting Lee; Edmond M Kwan; Arun A Azad; Shakher Ramdave; Andrew D Redfern; William Macdonald; Alex Guminski; Edward Hsiao; Wei Chua; Peter Lin; Alison Y Zhang; Margaret M McJannett; Martin R Stockler; John A Violet; Scott G Williams; Andrew J Martin; Ian D Davis
Journal:  Lancet       Date:  2021-02-11       Impact factor: 79.321

8.  177Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine.

Authors:  Johannes Czernin; Jeremie Calais
Journal:  J Nucl Med       Date:  2021-06-24       Impact factor: 10.057

9.  Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Authors:  Oliver Sartor; Johann de Bono; Kim N Chi; Karim Fizazi; Ken Herrmann; Kambiz Rahbar; Scott T Tagawa; Luke T Nordquist; Nitin Vaishampayan; Ghassan El-Haddad; Chandler H Park; Tomasz M Beer; Alison Armour; Wendy J Pérez-Contreras; Michelle DeSilvio; Euloge Kpamegan; Germo Gericke; Richard A Messmann; Michael J Morris; Bernd J Krause
Journal:  N Engl J Med       Date:  2021-06-23       Impact factor: 91.245

10.  PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis.

Authors:  Robert Seifert; Katharina Kessel; Katrin Schlack; Manuel Weber; Ken Herrmann; Maximilian Spanke; Wolfgang P Fendler; Boris Hadaschik; Jens Kleesiek; Michael Schäfers; Matthias Weckesser; Martin Boegemann; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-09-24       Impact factor: 9.236

View more
  4 in total

1.  The VISION Forward: Recognition and Implication of PSMA-/18F-FDG+ mCRPC.

Authors:  Hossein Jadvar
Journal:  J Nucl Med       Date:  2021-12-21       Impact factor: 11.082

2.  PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy.

Authors:  Jeremie Calais; Johannes Czernin
Journal:  J Nucl Med       Date:  2021-11       Impact factor: 11.082

Review 3.  Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer.

Authors:  Jiaxian Chen; Lin Qi; Yongxiang Tang; Guyu Tang; Yu Gan; Yi Cai
Journal:  Front Cell Dev Biol       Date:  2022-08-12

Review 4.  Radiolabeled PSMA Inhibitors.

Authors:  Oliver C Neels; Klaus Kopka; Christos Liolios; Ali Afshar-Oromieh
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.